Lataa...
PPARγ Antagonist Gleevec Improves Insulin Sensitivity and Promotes the Browning of White Adipose Tissue
Blocking phosphorylation of peroxisome proliferator–activated receptor (PPAR)γ at Ser(273) is one of the key mechanisms for antidiabetes drugs to target PPARγ. Using high-throughput phosphorylation screening, we here describe that Gleevec blocks cyclin-dependent kinase 5–mediated PPARγ phosphorylati...
Tallennettuna:
| Julkaisussa: | Diabetes |
|---|---|
| Päätekijät: | , , , , , , , , , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
American Diabetes Association
2016
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5314706/ https://ncbi.nlm.nih.gov/pubmed/26740599 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/db15-1382 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|